| Old Articles: <Older 6141-6150 Newer> |
|---|
 |
The Motley Fool
January 21, 2010
Brian Orelli |
The Noble Gesture That Wasn't There may be a motive behind Glaxo helping to develop malaria treatments.   |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
Chemistry World
January 20, 2010
Phil Taylor |
Screw tightens on pay-for-delay drug deals Scrutiny of the tactics used by pharmaceutical companies to delay the entry of generics onto the market is rising on both sides of the Atlantic amid claims that the practice is costing consumers billions every year. |
The Motley Fool
January 19, 2010
Brian Orelli |
Pfizer Gets Serious About Generics Serious, as in a potential $4-billion-purchase serious. |
InternetNews
January 15, 2010 |
Hard Drive Theft Nets Health Data of Thousands Breach of protocol leads to the potential loss of Kaiser Permanente patient data in California. |
The Motley Fool
January 15, 2010
Brian Orelli |
The Odor Lingers at Johnson & Johnson The company has to recall products because of a smelly problem. |
The Motley Fool
January 15, 2010
Brian Orelli |
Oops, Sorry About That, Pfizer The FDA says there's no problem with Spiriva after all. |
The Motley Fool
January 15, 2010
Tim Hanson |
This Is What a Real Growth Opportunity Looks Like Dr. Reddy's Laboratories is a small company with a wide market opportunity that stands to benefit from meaningful macroeconomic tailwinds. |
BusinessWeek
January 14, 2010
Ellen Gibson |
The Hunt for an Autism Drug Armed with fresh medical insights, drug companies are redoubling their efforts to address the disease's complex causes. |
BusinessWeek
January 14, 2010
Rob Waters |
Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology. |
| <Older 6141-6150 Newer> Return to current articles. |
